PMID- 34458259
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210831
IS  - 2296-634X (Print)
IS  - 2296-634X (Electronic)
IS  - 2296-634X (Linking)
VI  - 9
DP  - 2021
TI  - Differential and Prognostic Significance of HOXB7 in Gliomas.
PG  - 697086
LID - 10.3389/fcell.2021.697086 [doi]
LID - 697086
AB  - Diffuse glioma is the most common primary tumor of the central nervous system. 
      The prognosis of the individual tumor is heavily dependent on its grade and 
      subtype. Homeobox B7 (HOXB7), a member of the homeobox family, is abnormally 
      overexpressed in a variety of tumors. However, its function in glioma is unclear. 
      In this study, HOXB7 mRNA and protein expression levels were analyzed in 401 
      gliomas from the CGGA RNA-seq database (325 cases) and our hospital (76 cases). 
      HOXB7 expression, at both mRNA and protein levels, were upregulated in 
      glioblastoma (GBM) and isocitrate dehydrogenase 1 (IDH1) wild-type glioma 
      tissues. Kaplan-Meier with log-rank test showed that patients with high HOXB7 
      expression had a poor prognosis (p < 0.0001). Moreover, HOXB7 protein was deleted 
      in 90.9% (20/22) of oligodendrogliomas and 13.0% (3/23) of astrocytomas. The 
      sensitivity and specificity of HOXB7 protein deletion in oligodendroglioma were 
      90.9% (20/22) and 87.0% (20/23), respectively. To verify the reliability of using 
      HOXB7 in differentiating oligodendroglioma, we used 1p/19q fluorescence in situ 
      hybridization (FISH) testing as a positive control. The Cohen's kappa coefficient 
      of HOXB7 immunohistochemistry staining and 1p/19q FISH testing was 0.778 (95% CI: 
      0.594-0.962, p < 0.001). In conclusion, HOXB7 is an independent predictor of poor 
      prognosis in all grade gliomas. Additionally, HOXB7 is also a highly sensitive 
      and specific indicator to differentiate oligodendroglioma from astrocytoma.
CI  - Copyright (c) 2021 Zhou, Liang, Deng, Ng, Li, Lv, Chen, Yang, Ma, Ma and Wang.
FAU - Zhou, Xingang
AU  - Zhou X
AD  - Department of Pathology, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Liang, Tingyu
AU  - Liang T
AD  - Department of Neurosurgery, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Deng, Jinhai
AU  - Deng J
AD  - Key Laboratory of Medical Immunology, School of Basic Medical Sciences, Peking 
      University Center for Human Disease Genomics, Peking University Health Science 
      Center, Beijing, China.
AD  - Richard Dimbleby Department of Cancer Research, Comprehensive Cancer Center, 
      Kings College London, London, United Kingdom.
FAU - Ng, Kenrick
AU  - Ng K
AD  - Department of Medical Oncology, University College London Cancer Institute, 
      London, United Kingdom.
FAU - Li, Man
AU  - Li M
AD  - Department of Pathology, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Lv, Chunxin
AU  - Lv C
AD  - Geriatric Department, Minhang Hospital, Fudan University, Shanghai, China.
FAU - Chen, Jiamin
AU  - Chen J
AD  - Department of Pathology, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Yang, Kun
AU  - Yang K
AD  - Department of Pathology, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Ma, Zhiyuan
AU  - Ma Z
AD  - Department of Pathology, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Ma, Wenping
AU  - Ma W
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Wang, Peng
AU  - Wang P
AD  - Department of Pathology, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20210811
PL  - Switzerland
TA  - Front Cell Dev Biol
JT  - Frontiers in cell and developmental biology
JID - 101630250
PMC - PMC8385304
OTO - NOTNLM
OT  - HOXB7
OT  - astrocytoma
OT  - immunohistochemistry
OT  - oligodendroglioma
OT  - prognosis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/08/31 06:00
MHDA- 2021/08/31 06:01
PMCR- 2021/01/01
CRDT- 2021/08/30 06:01
PHST- 2021/04/18 00:00 [received]
PHST- 2021/07/22 00:00 [accepted]
PHST- 2021/08/30 06:01 [entrez]
PHST- 2021/08/31 06:00 [pubmed]
PHST- 2021/08/31 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fcell.2021.697086 [doi]
PST - epublish
SO  - Front Cell Dev Biol. 2021 Aug 11;9:697086. doi: 10.3389/fcell.2021.697086. 
      eCollection 2021.